Kineta, Samsung Biologics partner on solid-tumor therapy

By The Science Advisory Board staff writers

July 21, 2021 -- Samsung Biologics has inked a deal providing end-to-end development and manufacturing services to advance Kineta's anti-V-domain immunoglobulin suppressor of T-cell activation (VISTA) antibody being developed for the treatment of solid tumors.

Samsung will provide cell line development, clinical drug substance, and drug product manufacturing services to support an investigational new drug application for Kineta's KVA12.1. Cell line development will be completed at Samsung's San Francisco site, and clinical trial materials will be made at its South Korea site.

VISTA is a key driver of the immunosuppressive tumor microenvironment and is overexpressed on myeloid-derived suppressor cells and regulatory T cells. It is a critical myeloid cell immune checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. The goal with KVA12.1 use is to reprogram the tumor microenvironment in hard-to-treat solid tumors.

Samsung Biologics readies mRNA vaccine drug substance production
Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.
Samsung Biologics breaks ground on 'super plant'
Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.
Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...
Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter